CVC (COVID-19 Vaccine Corporation Ltd.) proposes a unique approach to the development of a COVID-19 vaccine utilising New Zealand technology. We believe our approach has the potential to augment and improve the immune response of other COVID-19 vaccines while being cost-efficient to manufacture at scale.

Preliminary results from a number of candidates are extremely promising with reported protection over 90%. However, there are still cases where those vaccinated are not protected. Furthermore, there is always a chance that the SARS-CoV-2 virus may mutate to make the current lead vaccines less effective. CVC's vaccine is designed to overcome these issues.

CVC has been set up by four individuals in New Zealand who are all experts in their pharmaceutical and biotechnology fields. Expertise includes vaccine development and production.